Skip to content
type1.science
N/A (device / behavioral)CompletedNCT02463097

MiniMed 670G pivotal in-home hybrid closed-loop study

Pivotal in-home study supporting the first FDA-approved commercial hybrid closed-loop system for type 1 diabetes.

Primary endpoints

  • Safety and glucose outcomes during in-home hybrid closed-loop use

Results so far

Published pivotal evidence supported safe home use and improved glucose outcomes from baseline. Pediatric follow-on evidence supported expansion down to age 7, with TIR increasing from 56.2% to 65.0% in ages 7-13.

The full picture

This is the historical trial lineage for commercial AID: the 670G was not the best algorithm by modern standards, but it established that a hybrid closed-loop system could be used at home safely enough for regulatory approval.